| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Caligan Partners LP | 10% | $7,611,193 | 15,856,653 | Caligan Partners LP | 31 Dec 2024 | |||
| ARMISTICE CAPITAL, LLC | 10% | 0% | $6,464,900 | +$70,528 | 9,235,571 | +1.1% | Armistice Capital, LLC | 31 Mar 2025 |
| PERCEPTIVE ADVISORS LLC | 1.6% | -70% | $711,111 | -$1,559,841 | 1,481,481 | -69% | Perceptive Advisors LLC | 31 Mar 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 568 shares of Verrica Pharmaceuticals Inc. - Common Stock, $0.0001 par value (VRCA). This represents 0% of the company’s total 92,448,158 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 568 | $301 | -$13,341,049 | $0.53 | 1 |
| 2025 Q2 | 24,695,954 | $13,342,110 | -$2,100,368 | $0.53 | 52 |
| 2025 Q1 | 29,469,428 | $13,048,356 | -$1,283,553 | $0.44 | 72 |
| 2024 Q4 | 29,927,289 | $20,929,400 | +$9,291,917 | $0.70 | 78 |
| 2024 Q3 | 14,834,226 | $21,508,388 | -$32,397,532 | $1.45 | 78 |
| 2024 Q2 | 18,643,979 | $135,914,267 | +$6,591,368 | $7.29 | 73 |
| 2024 Q1 | 17,749,027 | $105,074,136 | -$1,510,319 | $5.92 | 61 |
| 2023 Q4 | 0 | $0 | -$70,707 | $0.53 | 0 |
| 2023 Q3 | 15,050,197 | $58,469,549 | +$1,486,479 | $3.88 | 66 |
| 2023 Q2 | 14,600,620 | $84,244,102 | +$9,113,868 | $5.77 | 63 |
| 2023 Q1 | 12,943,792 | $84,133,481 | +$14,995,061 | $6.50 | 59 |
| 2022 Q4 | 10,815,342 | $29,741,148 | -$1,571,507 | $2.75 | 48 |
| 2022 Q3 | 10,244,689 | $29,913,489 | -$2,466,850 | $2.92 | 45 |
| 2022 Q2 | 11,235,753 | $21,571,342 | +$4,530,352 | $1.92 | 50 |
| 2022 Q1 | 8,782,869 | $71,240,740 | -$773,551 | $8.11 | 45 |
| 2021 Q4 | 8,952,154 | $81,994,119 | -$7,322,253 | $9.16 | 42 |
| 2021 Q3 | 9,169,244 | $114,606,238 | -$8,445,470 | $12.50 | 49 |
| 2021 Q2 | 9,937,155 | $112,292,153 | -$1,688,098 | $11.30 | 53 |
| 2021 Q1 | 9,927,525 | $150,401,616 | +$14,966,026 | $15.15 | 51 |
| 2020 Q4 | 8,954,333 | $103,061,539 | -$551,970 | $11.51 | 43 |
| 2020 Q3 | 8,897,757 | $68,868,527 | +$715,296 | $7.74 | 42 |
| 2020 Q2 | 8,208,638 | $90,375,883 | -$417,315 | $11.01 | 42 |
| 2020 Q1 | 8,250,290 | $90,173,906 | -$4,838,695 | $10.93 | 43 |
| 2019 Q4 | 9,194,269 | $143,924,393 | -$4,189,296 | $15.89 | 50 |
| 2019 Q3 | 9,262,104 | $136,707,439 | +$4,275,668 | $14.76 | 41 |
| 2019 Q2 | 9,017,971 | $104,753,394 | +$2,569,853 | $11.62 | 40 |
| 2019 Q1 | 8,801,312 | $96,812,441 | +$5,628,066 | $10.81 | 38 |
| 2018 Q4 | 8,444,994 | $68,824,024 | -$1,839,443 | $8.15 | 40 |
| 2018 Q3 | 8,239,588 | $133,895,000 | -$359,375 | $16.25 | 44 |
| 2018 Q2 | 8,314,673 | $162,073,973 | +$162,074,012 | $19.73 | 28 |